Buphenyl Related Published Studies
Well-designed clinical trials related to Buphenyl (Phenylbutyrate)
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic
encephalopathy. [2014]
Phenylbutyrate Mouthwash Mitigates Oral Mucositis During Radiotherapy or Chemoradiotherapy in Patients with Head and Neck Cancer. [2011.08.11]
Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. [2010.06]
Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. [2007.01.02]
Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. [2002.07]
A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. [1998.02]
Well-designed clinical trials possibly related to Buphenyl (Phenylbutyrate)
Owner assessment in judging the efficacy of airway disease treatment. [2011.03]
Owner assessment in judging the efficacy of airway disease treatment. [2011]
Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel
short chain fatty acid derivative, in a phase 1, double-blind,
placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers. [2011]
The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppression. [2010.12]
New insights in nutritional management and amino acid supplementation in urea cycle disorders. [2010]
Drug treatment for spinal muscular atrophy types II and III. [2009.01.21]
[Heparan sulphate in association with indobufen in the treatment of chronic peripheral obliterative arteriopathy of the lower extremities. Controlled clinical trial] [1998.11]
Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. [1997.08.19]
Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. [1997.05]
Relative bioavailability of different butamirate citrate preparations after single dose oral administration to 18 healthy volunteers. [1997.03]
Effects of indobufen and pentoxifylline on walking capacity and hemostasis in patients with intermittent claudication: results of six months of treatment. [1997.03]
A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study). Ticlopidine Indobufen Stroke Study. [1997.01]
Reduction by indobufen of neutrophil activation in peripheral arterial occlusive disease. [1996.03]
A prostacyclin-sparing effect of indobufen vs. aspirin. [1996.03]
Lack of a pharmacokinetic interaction between ciprofloxacin and fenbufen. [1994.08]
[The effect of indobufen on patency in femoro-popliteal/crural bypass using artificial grafts] [1994.05]
Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting. [1994.04]
[Italian Study on Atrial Fibrillation (SIFA): status report] [1993.12]
Factors influencing 1-year patency of coronary artery saphenous vein grafts. Studio Indobufene nel Bypass Aortocoronarico (SINBA). [1993.11]
Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. [1993.09]
Prophylaxis of recurrent deep venous thrombosis. A randomized, prospective study using indobufen and graduated elastic compression stockings. [1993.09]
Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. [1993.04]
Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study. [1993.01]
[The effect of indobufen on aortocoronary bypass patency after 1 week and after 1 year] [1993]
Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass. [1992.04]
The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex vivo and for the increase in bleeding time by indobufen in man. [1992.02.03]
Bleeding time and antiplatelet agents in normal volunteers. [1992]
Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease. [1992]
Indobufen versus placebo in the prevention of restenosis after carotid endarterectomy: a double-blind pilot study. [1991.05]
A linear model suitable for assessing graft patency in controlled clinical trials. SINBA Group. [1990.12]
Inhibition of tissue prostaglandin synthesis during third molar surgery: use of preoperative fenbufen. [1990.08]
The effect of ibustrin on early aortocoronary bypass patency. [1990]
Comparative evaluation of the antitussive activity of butamirate citrate linctus versus clobutinol syrup. [1990]
[Plasma and tissue concentrations of biphenylacetic acid following 1 week oral fenbufen medication and topical administration of Felbinac gel on the knee joint] [1989.11]
Efficacy of indobufen in the treatment of intermittent claudication. [1988.08]
The effect of indobufen on the thrombogenic potential of a Dacron prosthesis in an artificial circulation. [1988.08]
A double-blind placebo-controlled trial of indobufen in the prophylaxis of migraine. [1988.06]
Other research related to Buphenyl (Phenylbutyrate)
Long-term phenylbutyrate administration prevents memory deficits in Tg2576 mice by decreasing Abeta. [2011.06.01]
Phenylbutyrate improves nitrogen disposal via an alternative pathway without eliciting an increase in protein breakdown and catabolism in control and ornithine transcarbamylase-deficient patients. [2011.06]
Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. [2011.04.29]
Sodium phenylbutyrate, a drug with known capacity to reduce endoplasmic reticulum stress, partially alleviates lipid-induced insulin resistance and beta-cell dysfunction in humans. [2011.03]
Phenylbutyrate therapy for maple syrup urine disease. [2011.02.15]
Phenylbutyrate counteracts Shigella mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia: a potential therapeutic strategy. [2011]
Sodium 4-phenylbutyrate protects against spinal cord ischemia by inhibition of endoplasmic reticulum stress. [2010.12]
Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. [2010.07]
Sodium 4-phenylbutyrate ameliorates the effects of cataract-causing mutant gammaD-crystallin in cultured cells. [2010.06.04]
Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults
with cirrhosis. [2010]
The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response. [2009.12]
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. [2009.10.01]
Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. [2009.06]
Phase 2 study of sodium phenylbutyrate in ALS. [2009.04]
Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. [2008.02]
Pilot study of sodium phenylbutyrate as adjuvant in cyclophosphamide-resistant endemic Burkitt's lymphoma. [2007.12]
Sodium phenylbutyrate in Huntington's disease: a dose-finding study. [2007.10.15]
4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality. [2007.08.24]
Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury. [2007.06.15]
Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. [2007.06]
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. [2007.04]
Retinal ischemic injury rescued by sodium 4-phenylbutyrate in a rat model. [2007.03]
Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. [2007.03]
Enhancing engraftment of islets using perioperative sodium 4-phenylbutyrate. [2006.12.20]
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. [2006.02]
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. [2005.06.10]
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. [2005.04]
[5-Aza-2'-deoxycytidine enhances differentiation and apoptosis induced by phenylbutyrate in Kasumi-1 cells] [2005.03]
Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. [2005.02]
HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells. [2004.11.05]
Sodium 4-phenylbutyrate protects against cerebral ischemic injury. [2004.10]
Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. [2004.09]
Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. [2004.07]
Pilot trial of phenylbutyrate in spinal muscular atrophy. [2004.02]
Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. [2004.01]
Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by phenylbutyrate on L1210 leukemic cells. [2004.01]
Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. [2004]
Mutations in distant residues moderately increase the enantioselectivity of Pseudomonas fluorescens esterase towards methyl 3bromo-2-methylpropanoate and ethyl 3phenylbutyrate. [2003.05.09]
Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. [2003.03]
PEX11alpha is required for peroxisome proliferation in response to 4-phenylbutyrate but is dispensable for peroxisome proliferator-activated receptor alpha-mediated peroxisome proliferation. [2002.12]
Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. [2002.12]
Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. [2002.09]
Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans. [2002.06]
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. [2002.04]
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. [2001.10]
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. [2001.08]
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. [2001.08]
Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate. [2001.05]
Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients. [2001.04]
Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. [2001.02.15]
Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. [2000.12]
Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate. [2000.06.15]
[Anti-atherosclerotic efficacy of quercetin and sodium phenylbutyrate in rabbits] [2000]
Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. [1999.12]
Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid. [1999.08]
Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. [1999.08]
Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea. [1998.06.30]
Phenylbutyrate-induced glutamine depletion in humans: effect on leucine metabolism. [1998.05]
|